Dr. Geoffrey Sher

About Dr. Geoffrey Sher

Treatments Offered by Dr. Geoffrey Sher

In vitro fertilization (IVF) Intra-Uterine Insemination (IUI) Intracytoplasmic Sperm Injection (ICSI) egg freezing Fertility Testing Fertility Options For LGBTQIA+ Third-Party Parenting Egg Donation Sperm Donation Embryo Donation Gestational Surrogacy Pre-implantation Genetic Testing (PGT)

more...

Awards & Recognitions

1. Dr. Sher established the first private IVF program in the United States in 1982.

2. He expanded his practice to include several centers throughout California before founding the first SIRM – in Las Vegas.

3. In one record-setting case, a couple journeyed from Melbourne, Australia, after experiencing 22 consecutive IVF failures. After a single IVF attempt, the couple finally had a baby!

4. Dr. Sher has more than 200 scientific papers and abstracts to his credit. He has authored one of the most widely read books on IVF, In Vitro Fertilization, the A.R.T. of Making Babies.

5. Influential in the births of more than 17,000 babies

6. 1982: First to recommend the exclusive use of gonadotropins to stimulate follicular development for IVF.

7. 1983: First to introduce Intrauterine Insemination (IUI) of washed sperm for treating certain forms of infertility.

8. 1989: First to report on ultrasound appearance and thickness of the uterine lining (endometrium) as a predictor of IVF success.

9. 1993: First to introduce the technique of “Prolonged Coasting” for cases of Severe Ovarian Hyperstimulation. This treatment protocol has virtually eliminated the life-endangering effects of this condition as well as eliminating the need to cancel the patient’s IVF cycle.

10. 1994: First to identify and treat immune factors affecting implantation potential of embryos in certain women.

11. 1997: First to introduce Viagra to enhance the thickness of the uterine lining in IVF patients.

12. 1998: First to recommend the selective use of intravenous gammaglobulin for the treatment of certain forms of Immunologic Implantation Dysfunction (IID) in IVF.

13. 2000: First to introduce a new protocol of ovarian stimulation, the agonist/antagonist conversion protocol (A/ACP) to improve egg/embryo quality in response to gonadotropin stimulation. This also led to the addition of advanced “priming” with estradiol valerate (A/ACP-E2V) to further augment the response of women with reduced ovarian reserve (“poor responders”).

14. 2003: First to measure soluble Human Leukocyte Antigen-G (sHLA-G) in the media surrounding early individual embryos and use this genetic marker to identify the “best individual embryos” (the ones that are most likely to implant and produce a viable pregnancy) for transfer to the uterus.

15. 2005: First to show, by using Pre-Implantation Genetic Testing (PGT) with Comparative Genomic Hybridization (CGH), that an embryo resulting from fertilization of a chromosomally normal (euploid egg), has a much improved ability to implant successfully and produce a normal baby. This method which tests egg/embryo “competence” is likely to vastly improve IVF results and lead to single embryo transfers, thereby minimizing the risk of multiple pregnancies.

16. 2007: First to show, by using PGT with CGH that an embryo resulting from fertilization of a euploid egg (i.e. an egg that has all of its chromosomes present), has a much-improved ability to implant successfully and produce a normal baby. To date, more than 400 babies have been born using this technique.

17. 2008: First to apply PGT with metaphase CGH to the selection of chromosomally intact eggs for cryobanking, leading to a four to six-fold improvement in the birth rate per frozen egg over that which had been previously reported. To date, many babies have been born from his use of CGH-tested eggs.

18. 2014: Supplanted CGH embryo testing with a new PGT method known as Next Generation Gene Sequencing (NGS) for testing the competency of embryos and eggs.